199 related articles for article (PubMed ID: 34318391)
1. Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
Jerzak KJ; Lipton N; Nofech-Mozes S; Boles D; Slodkowska E; Pond GR; Warner E
Breast Cancer Res Treat; 2021 Oct; 189(3):797-806. PubMed ID: 34318391
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.
Labrosse J; Abdennebi I; Thibault L; Laas E; Merckelbagh H; Morel C; Lam T; Lae M; Reyal F; Hamy AS
Breast; 2018 Dec; 42():61-67. PubMed ID: 30179779
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
O'Sullivan CC; Irshad S; Wang Z; Tang Z; Umbricht C; Rosner GL; Christianson MS; Stearns V; Smith KL
Breast Cancer Res Treat; 2020 Apr; 180(3):695-706. PubMed ID: 32162192
[TBL] [Abstract][Full Text] [Related]
5. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
7. Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk.
Goddard ET; Bassale S; Schedin T; Jindal S; Johnston J; Cabral E; Latour E; Lyons TR; Mori M; Schedin PJ; Borges VF
JAMA Netw Open; 2019 Jan; 2(1):e186997. PubMed ID: 30646210
[TBL] [Abstract][Full Text] [Related]
8. Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period.
Lefrère H; Floris G; Schmidt MK; Neven P; Warner E; Cardonick E; Peccatori FA; Loibl S; Maggen C; De Mulder H; Jerzak KJ; Lambrechts D; Lenaerts L; Amant F
Data Brief; 2021 Oct; 38():107354. PubMed ID: 34557571
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.
Lefrère H; Floris G; Schmidt MK; Neven P; Warner E; Cardonick E; Peccatori FA; Loibl S; Maggen C; De Mulder H; Jerzak KJ; Lambrechts D; Lenaerts L; Amant F
Eur J Cancer; 2021 Sep; 155():13-24. PubMed ID: 34330022
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
14. BIK and GRP78 protein expression as possible markers of response to preoperative chemotherapy and survival in breast cancer.
María Teresa de Jesús CD; Agni Jaim MG; Cindy Karina VV; Víctor Alberto OC; Nicolás RT; Verónica GO; Fabio Abdel SG; Patricia PS; Sergio FH; Eunice LM
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):245-252. PubMed ID: 33678323
[TBL] [Abstract][Full Text] [Related]
15. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.
Mouabbi JA; Chand M; Asghar IA; Sakhi R; Ockner D; Dul CL; Hadid T; Aref A; Rimawi MF; Hoyos V
Cancer Med; 2021 Jul; 10(14):4790-4795. PubMed ID: 34080777
[TBL] [Abstract][Full Text] [Related]
16. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
17. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Adams S; Gray RJ; Demaria S; Goldstein L; Perez EA; Shulman LN; Martino S; Wang M; Jones VE; Saphner TJ; Wolff AC; Wood WC; Davidson NE; Sledge GW; Sparano JA; Badve SS
J Clin Oncol; 2014 Sep; 32(27):2959-66. PubMed ID: 25071121
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
